HCW Biologics reports equity above $2.5M after deals; awaits Nasdaq compliance decision

HCW Biologics Inc.

Warrant inducement netted $3.8M; holders exercised 1.51M shares at $2.66, received new warrants at $2.41.
Issued shares under standby equity line in Q4 2025 for net proceeds of $363,858, boosting equity.
Settled $7.4M legal fees for $2.0M cash ($500K paid, $1.5M due on license fee receipt); expects $5.4M equity gain.
Company states stockholders' equity now exceeds $2.5M minimum; awaits Nasdaq formal verification.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.